Birabresib - OncoEthix

Drug Profile

Birabresib - OncoEthix

Alternative Names: MK 8628; OTX 015; Y-803

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Merck & Co; Mitsubishi Tanabe Pharma Corporation; OncoEthix
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Small molecules; Triazoles
  • Mechanism of Action BRD2-protein-inhibitors; BRD3 protein inhibitors; BRD4-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Glioblastoma
  • Phase I Haematological malignancies
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 23 May 2017 Merck terminates a phase I trial in Solid tumours (Late-stage disease) in USA, France, Switzerland, Canada, Spain and Belgium (PO) (NCT02698176)
  • 03 Mar 2017 Oncoethix completes a phase I trial in Solid tumours in France and Canada (PO) (NCT02259114)
  • 28 Dec 2016 OTX 015 is still in phase I trials for Haematological malignancies in France, Italy and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top